SMALL CELL LUNG CANCER (SCLC)

This study is testing a new two-drug combination (alisertib pills and paclitaxel infusions) for adults with small cell lung cancer that has continued to grow despite prior chemotherapy and immunotherapy. The main goal is to find the highest dose of alisertib that can be safely gi…

This study is testing whether adding two newer drugs (bemotuzumab and anlotinib) to standard chemotherapy and radiation can better control extensive-stage small cell lung cancer. About 25 patients who haven't had prior treatment will receive the combination therapy in phases, sta…

This is the first study in people to test the safety and early effects of an experimental cell therapy called ML261. It is for adults with advanced small cell lung cancer or certain related neuroendocrine cancers that have come back or stopped responding to standard treatments. D…

This study is testing whether a new medicine called PF-08634404 works better when given with standard chemotherapy for a rare, aggressive form of lung cancer called transformed small cell lung cancer. The trial will enroll 40 adults who haven't received treatment for this specifi…

This study is testing whether penfluridol, a medication long used for mental health, can help control aggressive small cell cancers of the lung or cervix that have returned or stopped responding to standard treatments. It will enroll 33 adults who have already tried at least two …

This study is testing whether adding a new medicine called obrixtamig to standard treatment helps people with advanced small cell lung cancer live longer. About 670 adults who haven't had treatment for this advanced stage will be randomly assigned to receive either the standard t…

This study is testing the safety and effectiveness of combining two drugs, lurbinectedin and osimertinib, for a rare and aggressive type of lung cancer called transformed small cell lung cancer. It will involve about 16 adults whose cancer started as one type and changed into thi…